Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Philadelphia-Negative Chronic Myeloproliferative Neoplasms during the COVID-19 Pandemic: Challenges and Future Scenarios
Francesca Palandri, Massimo Breccia, Valerio De Stefano, et al.
Cancers (2021) Vol. 13, Iss. 19, pp. 4750-4750
Open Access | Times Cited: 11

Showing 11 citing articles:

Ten years after ruxolitinib approval for myelofibrosis: a review of clinical efficacy
Naveen Pemmaraju, Prithviraj Bose, Raajit K. Rampal, et al.
Leukemia & lymphoma/Leukemia and lymphoma (2023) Vol. 64, Iss. 6, pp. 1063-1081
Open Access | Times Cited: 27
Ten years of treatment with ruxolitinib for myelofibrosis: a review of safety
Srđan Verstovšek, Ruben A. Mesa, Robert A. Livingston, et al.
Journal of Hematology & Oncology (2023) Vol. 16, Iss. 1
Open Access | Times Cited: 19
Fedratinib, the first selective JAK2 inhibitor approved for treatment of myelofibrosis – an option beyond ruxolitinib
Chandan Saha, Claire Harrison
Expert Review of Hematology (2022) Vol. 15, Iss. 7, pp. 583-595
Closed Access | Times Cited: 9
Epidemiology and disease characteristics of myelofibrosis: a comparative analysis between Italy and global perspectives
Massimo Breccia, Francesca Palandri, Nicola Polverelli, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 1
Longer-term response to SARS-CoV-2 vaccine in MPN patients: Role of ruxolitinib and disease severity
Giuseppe Auteri, Daniela Bartoletti, Christian Di Pietro, et al.
Leukemia Research (2022) Vol. 116, pp. 106819-106819
Open Access | Times Cited: 6
Covid-19 in Philadelphia-negative myeloproliferative neoplasms: a GIMEMA survey on incidence, clinical management and vaccine
Massimo Breccia, Alfonso Piciocchi, Monica Messina, et al.
Leukemia (2022) Vol. 36, Iss. 10, pp. 2548-2550
Open Access | Times Cited: 5
Philadelphia-negative chronic myeloproliferative neoplasm follow-up: when the phone rings. Changes during the COVID-19 pandemic and patient satisfaction. Experience in 30 health centers in Spain
Ariana Ortuzar, María Laura Fox, Juan Antonio Vera, et al.
Annals of Hematology (2022) Vol. 102, Iss. 2, pp. 447-456
Open Access | Times Cited: 3
MPN and thrombosis was hard enough . . . now there's COVID-19 thrombosis too
Anna Falanga
Hematology (2021) Vol. 2021, Iss. 1, pp. 710-717
Open Access | Times Cited: 3
Severity of SARS-CoV-2 infection in myelofibrosis patients treated with ruxolitinib: Observational, prospective, of the case-control type study
Vera Stoeva, Konstantin Tachkov
GSC Biological and Pharmaceutical Sciences (2023) Vol. 22, Iss. 3, pp. 197-203
Open Access
Analysis of the Clinical Significance and Safety of Interferon in the Treatment of Chronic Myeloproliferative Tumors
Fenglei Yin, Juan Yin, Weixing Xu, et al.
Journal of Oncology (2022) Vol. 2022, pp. 1-5
Open Access
Clinical Course and Prophylaxis of COVID-19 in Patients with Myeloproliferative Diseases
В.М. Мицура, Д.К. Новик, Д.В. Кравченко, et al.
Гематология Трансфузиология Восточная Европа (2022), Iss. 2, pp. 103-109
Open Access
Page 1

Scroll to top